Recruiting
Phase 1

Ketamine

Sponsor:

Lindsay Maguire, MD

Code:

NCT06085937

Conditions

Suicide

Suicidal Ideation

Depression

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

Ketamine

Study Details

Brief summary:

There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.

Conditions

Suicide

Suicidal Ideation

Depression

Study ID

NCT06085937

Start date

May 1, 2024

Status verified date

Apr, 2026

Completion date

Apr, 2027

Anticipated

Primary completion date

Apr, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Acutely Suicidality ("yes" answer to any of items 4 or 5 on C-SSRS "Suicidal Ideation" category)
  • Require inpatient stabilization for SI or actions based on clinical observation and interview
  • Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus
  • Have a Glasgow Coma Score (GCS) of 15
  • Age 18-65

Exclusion Criteria:

  • Current or past history of psychosis
  • Current or recent (past 4 weeks) symptoms of mania/hypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater
  • History of ketamine use disorder
  • History of liver transplant
  • Pregnancy or breastfeeding
  • Imprisonment or inability to consent
  • Positive urine drug screen or serum alcohol level
  • Hypertension (SBP > 160 or DBP > 100 before administration of ketamine)
  • Hypotension (SBP < 90)
  • Presence of acute medical condition requiring admission to medical service
  • Allergy, intolerance, or previous adverse reaction to ketamine
  • Patient has 8+ lifetime ketamine exposures
  • The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition/procedure, medication that would contradindicate ketamine treatment)

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ketamine

All patients will receive the experimental drug.

Interventions

Ketamine

Patients will receive 0.2mg/kg of IV ketamine

Primary outcome measure

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 2 hours ]
  • Provider and Nursing Attitudes toward use of Ketamine for Suicidal Patients in the ED [Feasibility] [ Time Frame: 2 hours ]

Central Contacts and Locations

Central contacts

Lindsay Maguire, MD

913-588-3580lmaguire@kumc.edu

Lucas Lemar

llemar@kumc.edu

Locations

University of Kansas Medical Center Emergency Department

Recruiting

Kansas City, Kansas, United States, 66160

Contacts

Lindsay Maguire, MD

8048144509lmaguire@kumc.edu

More Information

Sponsor

Lindsay Maguire, MD

Last update posted

Apr 15, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Lindsay Maguire, MD on 2026-04-15.